An RNA molecule derived from Sendai virus DI particles induces antitumor immunity and cancer cell-selective apoptosis

Molecular Therapy

Volumn 24, Issue 1, 2016, Pages 135-145

  Liu, Li Wen ^a   Nishikawa, Tomoyuki ^a   Kaneda, Yasufumi ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 3; GENOMIC RNA; IVT B2 RNA; MITOCHONDRIAL ANTIVIRAL SIGNALING PROTEIN; MITOCHONDRIAL PROTEIN; PROPIOLACTONE; RETINOIC ACID INDUCIBLE PROTEIN I; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; VIRUS RNA; DOUBLE STRANDED RNA; MITOGEN ACTIVATED PROTEIN KINASE; NLK PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG CANCER; LUNG CANCER CELL LINE; MALE; MOUSE; NATURAL KILLER CELL; NONHUMAN; NOXA GENE; PROSTATE CANCER; PROSTATE CANCER CELL LINE; RNA STRUCTURE; SENDAI VIRUS; TRAIL GENE; TUMOR VOLUME; TUMOR XENOGRAFT; VIRUS ENVELOPE; VIRUS GENOME; VIRUS PARTICLE; VIRUS REPLICATION; VIRUS STRAIN; ANIMAL; CHEMISTRY; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; ONCOLYTIC VIROTHERAPY; PROSTATIC NEOPLASMS; SATELLITE VIRUS; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; DEFECTIVE VIRUSES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICE; MITOGEN-ACTIVATED PROTEIN KINASES; ONCOLYTIC VIROTHERAPY; PROSTATIC NEOPLASMS; RNA, DOUBLE-STRANDED; RNA, VIRAL; SENDAI VIRUS; TNF-RELATED APOPTOSIS-INDUCING LIGAND; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84957849485     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2015.201     Document Type: Article

References (35)

1. DeSantis, CE, Lin, CC, Mariotto, AB, Siegel, RL, Stein, KD, Kramer, JL., et al. (2014). Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin 64: 252-271
2. Gregory, CW, He, B, Johnson, RT, Ford, OH, Mohler, JL, French, FS., et al. (2001). A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res 61: 4315-4319
3. Lorence, RM, Rood, PA and Kelley, KW (1988). Newcastle disease virus as an antineoplastic agent: induction of tumor necrosis factor-alpha and augmentation of its cytotoxicity. J Natl Cancer Inst 80: 1305-1312
4. Coffey, MC, Strong, JE, Forsyth, PA and Lee, PW (1998). Reovirus therapy of tumors with activated Ras pathway. Science 282: 1332-1334
5. Saga, K and Kaneda, Y (2013). Virosome presents multimodel cancer therapy without viral replication. Biomed Res Int 2013: 764706
6. Kirn, D, Martuza, RL and Zwiebel, J (2001). Replication-selective virotherapy for cancer: biological principles, risk management and future directions. Nat Med 7: 781-787
7. Kelly, E and Russell, SJ (2007). History of oncolytic viruses: genesis to genetic engineering. Mol Ther 15: 651-659
8. Kurooka, M and Kaneda, Y (2007). Inactivated Sendai virus particles eradicate tumors by inducing immune responses through blocking regulatory T cells. Cancer Res 67: 227-236
9. Fujihara, A, Kurooka, M, Miki, T and Kaneda, Y (2008). Intratumoral injection of inactivated Sendai virus particles elicits strong antitumor activity by enhancing local CXCL10 expression and systemic NK cell activation. Cancer Immunol Immunother 57: 73-84
10. Kawaguchi, Y, Miyamoto, Y, Inoue, T and Kaneda, Y (2009). Efficient eradication of hormone-resistant human prostate cancers by inactivated Sendai virus particle. Int J Cancer 124: 2478-2487
11. Tanaka, M, Shimbo, T, Kikuchi, Y, Matsuda, M and Kaneda, Y (2010). Sterile alpha motif containing domain 9 is involved in death signaling of malignant glioma treated with inactivated Sendai virus particle (HVJ-E) or type I interferon. Int J Cancer 126: 1982-1991
12. Matsushima-Miyagi, T, Hatano, K, Nomura, M, Li-Wen, L, Nishikawa, T, Saga, K., et al. (2012). TRAIL and Noxa are selectively upregulated in prostate cancer cells downstream of the RIG-I/MAVS signaling pathway by nonreplicating Sendai virus particles. Clin Cancer Res 18: 6271-6283
13. Yoneyama, M, Kikuchi, M, Natsukawa, T, Shinobu, N, Imaizumi, T, Miyagishi, M., et al. (2004). The RNA helicase RIG-I has an essential function in double-stranded RNAinduced innate antiviral responses. Nat Immunol 5: 730-737
14. Kato, H, Takeuchi, O, Sato, S, Yoneyama, M, Yamamoto, M, Matsui, K., et al. (2006). Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature 441: 101-105
15. Yount, JS, Kraus, TA, Horvath, CM, Moran, TM and López, CB (2006). A novel role for viral-defective interfering particles in enhancing dendritic cell maturation. J Immunol 177: 4503-4513
16. Kato, H, Takeuchi, O, Mikamo-Satoh, E, Hirai, R, Kawai, T, Matsushita, K., et al. (2008). Length-dependent recognition of double-stranded ribonucleic acids by retinoic acidinducible gene-I and melanoma differentiation-associated gene 5. J Exp Med 205: 1601-1610
17. Luo, D, Ding, SC, Vela, A, Kohlway, A, Lindenbach, BD and Pyle, AM (2011). Structural insights into RNA recognition by RIG-I. Cell 147: 409-422
18. Lu, C, Xu, H, Ranjith-Kumar, CT, Brooks, MT, Hou, TY, Hu, F., et al. (2010). The structural basis of 5 triphosphate double-stranded RNA recognition by RIG-I C-terminal domain. Structure 18: 1032-1043
19. Schmidt, A, Rothenfusser, S and Hopfner, KP (2012). Sensing of viral nucleic acids by RIG-I: from translocation to translation. Eur J Cell Biol 91: 78-85
20. Strahle, L, Garcin, D and Kolakofsky, D (2006). Sendai virus defective-interfering genomes and the activation of interferon-beta. Virology 351: 101-111
21. Baum, A and García-Sastre, A (2011). Differential recognition of viral RNA by RIG-I. Virulence 2: 166-169
22. Martínez-Gil, L, Goff, PH, Hai, R, García-Sastre, A, Shaw, ML and Palese, P (2013). A Sendai virus-derived RNA agonist of RIG-I as a virus vaccine adjuvant. J Virol 87: 1290-1300
23. Baum, A, Sachidanandam, R and García-Sastre, A (2010). Preference of RIG-I for short viral RNA molecules in infected cells revealed by next-generation sequencing. Proc Natl Acad Sci USA 107: 16303-16308
24. Johnston, MD (1981). The characteristics required for a Sendai virus preparation to induce high levels of interferon in human lymphoblastoid cells. J Gen Virol 56: 175-184
25. Takahasi, K, Yoneyama, M, Nishihori, T, Hirai, R, Kumeta, H, Narita, R., et al. (2008). Nonself RNA-sensing mechanism of RIG-I helicase and activation of antiviral immune responses. Mol Cell 29: 428-440
26. Kaneda, Y (2010). Update on non-viral delivery methods for cancer therapy: possibilities of a drug delivery system with anticancer activities beyond delivery as a new therapeutic tool. Expert Opin Drug Deliv 7: 1079-1093
27. Kato, A, Ohnishi, Y, Kohase, M, Saito, S, Tashiro, M and Nagai, Y (2001). Y2, the smallest of the Sendai virus C proteins, is fully capable of both counteracting the antiviral action of interferons and inhibiting viral RNA synthesis. J Virol 75: 3802-3810
28. Kato, A, Cortese-Grogan, C, Moyer, SA, Sugahara, F, Sakaguchi, T, Kubota, T., et al. (2004). Characterization of the amino acid residues of sendai virus C protein that are critically involved in its interferon antagonism and RNA synthesis down-regulation. J Virol 78: 7443-7454
29. Takeuchi, K, Komatsu, T, Kitagawa, Y, Sada, K and Gotoh, B (2008). Sendai virus C protein plays a role in restricting PKR activation by limiting the generation of intracellular double-stranded RNA. J Virol 82: 10102-10110
30. Holm, GH, Zurney, J, Tumilasci, V, Leveille, S, Danthi, P, Hiscott, J., et al. (2007). Retinoic acid-inducible gene-I and interferon-beta promoter stimulator-1 augment proapoptotic responses following mammalian reovirus infection via interferon regulatory factor-3. J Biol Chem 282: 21953-21961
31. Goubau, D, Schlee, M, Deddouche, S, Pruijssers, AJ, Zillinger, T, Goldeck, M., et al. (2014). Antiviral immunity via RIG-I-mediated recognition of RNA bearing 5-diphosphates. Nature 514: 372-375
32. Marques, JT, Devosse, T, Wang, D, Zamanian-Daryoush, M, Serbinowski, P, Hartmann, R., et al. (2006). A structural basis for discriminating between self and nonself double-stranded RNAs in mammalian cells. Nat Biotechnol 24: 559-565
33. Dufour, JH, Dziejman, M, Liu, MT, Leung, JH, Lane, TE and Luster, AD (2002). IFNgamma-inducible protein 10 (IP-10; CXCL10)-deficient mice reveal a role for IP-10 in effector T cell generation and trafficking. J Immunol 168: 3195-3204
34. Angiolillo, AL, Sgadari, C, Taub, DD, Liao, F, Farber, JM, Maheshwari, S., et al. (1995). Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo. J Exp Med 182: 155-162
35. Kaneda, Y, Nakajima, T, Nishikawa, T, Yamamoto, S, Ikegami, H, Suzuki, N., et al. (2002). Hemagglutinating virus of Japan (HVJ) envelope vector as a versatile gene delivery system. Mol Ther 6: 219-226